NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
3.320
+0.030 (0.91%)
Sep 22, 2026, 4:00 PM EDT - Market closed
NRx Pharmaceuticals Revenue
NRx Pharmaceuticals had revenue of $1.10M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $3.39M. In the year 2025, NRx Pharmaceuticals had annual revenue of $1.23M.
Revenue (ttm)
$3.39M
Revenue Growth
n/a
P/S Ratio
42.32
Revenue / Employee
$117,034
Employees
29
Market Cap
143.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.23M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Caribou Biosciences | 10.04M |
| Korro Bio | 2.38M |
| Kazia Therapeutics | 1.27M |
| Spruce Biosciences | 697.00K |
NRXP News
- 7 days ago - NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’ - TheFly
- 7 days ago - NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine - GlobeNewsWire
- 8 days ago - GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 11 days ago - NRx Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 11 days ago - NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - GlobeNewsWire
- 13 days ago - NRx Pharmaceuticals Transcript: Moody Capital Disruptive Growth & Life Science Conference - Transcripts
- 14 days ago - NRx Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - NRx Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts